Cardiomyocytes from phorbol myristate acetate-activated mesenchymal stem cells restore electromechanical function in infarcted rat hearts

Despite the safety and feasibility of mesenchymal stem cell (MSC) therapy, an optimal cell type has not yet emerged in terms of electromechanical integration in infarcted myocardium. We found that poor to moderate survival benefits of MSC-implanted rats were caused by incomplete electromechanical in...

Full description

Saved in:
Bibliographic Details
Published inProceedings of the National Academy of Sciences - PNAS Vol. 108; no. 1; pp. 296 - 301
Main Authors Song, Heesang, Hwang, Hye Jin, Chang, Woochul, Song, Byeong-Wook, Cha, Min-Ji, Kim, Il-Kwon, Lim, Soyeon, Choi, Eun Ju, Ham, Onju, Lee, Chang Youn, Park, Jun-Hee, Lee, Se-Yeon, Choi, Eunmi, Lee, Chungkeun, Lee, Myoungho, Lee, Moon-Hyoung, Kim, Sung-Hou, Jang, Yangsoo, Hwang, Ki-Chul
Format Journal Article
LanguageEnglish
Published United States National Academy of Sciences 04.01.2011
National Acad Sciences
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Despite the safety and feasibility of mesenchymal stem cell (MSC) therapy, an optimal cell type has not yet emerged in terms of electromechanical integration in infarcted myocardium. We found that poor to moderate survival benefits of MSC-implanted rats were caused by incomplete electromechanical integration induced by tissue heterogeneity between myocytes and engrafted MSCs in the infarcted myocardium. Here, we report the development of cardiogenic cells from rat MSCs activated by phorbol myristate acetate, a PKC activator, that exhibited high expressions of cardiac-specific markers and Ca 2+ homeostasis-related proteins and showed adrenergic receptor signaling by norepinephrine. Histological analysis showed high connexin 43 coupling, few inflammatory cells, and low fibrotic markers in myocardium implanted with these phorbol myristate acetate-activated MSCs. Infarct hearts implanted with these cells exhibited restoration of conduction velocity through decreased tissue heterogeneity and improved myocardial contractility. These findings have major implications for the development of better cell types for electromechanical integration of cell-based treatment for infarcted myocardium.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
3Present address: Cardiovascular Research Institute, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642.
Contributed by Sung-Hou Kim, October 26, 2010 (sent for review September 2, 2010)
Author contributions: S.-H.K., Y.J., and K.-C.H. designed research; H.S., H.J.H., W.C., B.-W.S., M.-J.C., I.-K.K., S.L., E.J.C., O.H., C.Y.L., J.-H.P., S.-Y.L., E.C., C.L., M.L., and M.-H.L. performed research; S.-H.K., Y.J., and K.-C.H. contributed new reagents/analytic tools; H.S., H.J.H., W.C., B.-W.S., M.-J.C., I.-K.K., S.L., E.J.C., O.H., C.Y.L., J.-H.P., S.-Y.L., E.C., C.L., M.L., M.-H.L., S.-H.K., Y.J., and K.-C.H. analyzed data; and S.-H.K., Y.J., and K.-C.H. wrote the paper.
2Present address: Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06510.
1H.S., H.J.H., and W.C. contributed equally to this work.
ISSN:0027-8424
1091-6490
DOI:10.1073/pnas.1015873107